Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for INmune Bio, Inc. (INMB : NSDQ)
 
 • Company Description   
INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States.

Number of Employees: 10

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.16 Daily Weekly Monthly
20 Day Moving Average: 131,293 shares
Shares Outstanding: 17.95 (millions)
Market Capitalization: $128.49 (millions)
Beta: 2.44
52 Week High: $30.37
52 Week Low: $6.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.28% 4.89%
12 Week -27.31% -21.13%
Year To Date -29.80% -16.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
225 NE Mizner Blvd. Suite 640
-
Boca Raton,FL 33432
USA
ph: 858-964-3720
fax: -
james@haydenir.com http://www.inmunebio.com
 
 • General Corporate Information   
Officers
Raymond J. Tesi - Chief Executive Officer and President
David J. Moss - Chief Financial Officer; Treasurer; Secretary
Timothy Schroeder - Director
J. Kelly Ganjei - Director
Scott Juda - Director

Peer Information
INmune Bio, Inc. (CORR.)
INmune Bio, Inc. (RSPI)
INmune Bio, Inc. (CGXP)
INmune Bio, Inc. (BGEN)
INmune Bio, Inc. (GTBP)
INmune Bio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45782T105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 17.95
Most Recent Split Date: (:1)
Beta: 2.44
Market Capitalization: $128.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.69
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -21.87%
vs. Previous Quarter: 29.09%
Sales Growth
vs. Year Ago Period: 3,975.00%
vs. Previous Quarter: 0.00%
ROE
03/31/22 - -45.50
12/31/21 - -44.09
09/30/21 - -40.84
ROA
03/31/22 - -36.05
12/31/21 - -36.31
09/30/21 - -34.74
Current Ratio
03/31/22 - 23.89
12/31/21 - 18.95
09/30/21 - 18.91
Quick Ratio
03/31/22 - 23.89
12/31/21 - 18.95
09/30/21 - 18.90
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -9,613.82
12/31/21 - -16,762.43
09/30/21 - -82,320.69
Book Value
03/31/22 - 4.22
12/31/21 - 4.50
09/30/21 - 4.95
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.19
12/31/21 - 0.18
09/30/21 - 0.16
Debt-to-Capital
03/31/22 - 16.10
12/31/21 - 15.27
09/30/21 - 14.03
 

Powered by Zacks Investment Research ©